Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

D-Pharm Selects Tigermed for Trial of Stroke Drug

publication date: Nov 4, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
D-Pharm of Israel will entrust Hangzhou Tigermed Consulting Co. with a Phase III China clinical trial of its stroke treatment. Tigermed will also be in charge of China regulatory filings for DP-b99, a neuroprotective drug. Wanbang Biopharma, which will market the drug in China for D-Pharm, also signed the contract. More details....

Stock Symbol: (TASE: DPRM)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners